ijms-logo

Journal Browser

Journal Browser

Immune Cells in Allergy and Inflammation

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 4352

Special Issue Editor


E-Mail Website
Guest Editor
Department of Life Sciences, Brunel University London, Uxbridge, UK
Interests: innate immunity; nanomedicine; drug targeting; allergy; cancer; pregnancy; infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Allergy and inflammation are very common across the globe. In part, we can see and understand allergy and inflammation in various diseases, such as food allergy, allergic rhinitis, allergic asthma, allergic contact dermatitis, allergic conjunctivitis, eosinophilic gastroenteritis, acne vulgaris, atopic dermatitis, psoriasis, inflammatory bowel disease, etc. With the prevalence of infectious diseases today, allergy and inflammation are very important. Recently, it was reported that anaphylaxis (a serious allergic reaction that is rapid in onset and may cause death) or allergic reaction occurred following administration of the coronavirus disease 2019 vaccine. Focusing on differentiation factors, antibody–receptor interactions, ion channels, degranulation, enzymes, signaling molecules, transcription factors, morphological changes, and new cytokines could help to develop new strategies and drugs aimed at preventing and/or treating allergic and inflammatory diseases. Experimental papers, review articles, and clinical studies are welcome. On the other hand, mast cells play a pivotal role in initiating and amplifying allergic reactions. However, mast cells also play an important role in obesity-exacerbated dermatitis. Thus, converging research and interdisciplinary convergence research are also welcome.

Prof. Dr. Uday Kishore
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immune cells
  • Allergy
  • Inflammation
  • Mast cells
  • Neutrophils
  • Eosinophils
  • Macrophages
  • Monocytes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3005 KiB  
Article
Therapeutic Potential of Combining IL-6 and TNF Blockade in a Mouse Model of Allergic Asthma
by Olga A. Namakanova, Ekaterina A. Gorshkova, Ruslan V. Zvartsev, Sergei A. Nedospasov, Marina S. Drutskaya and Ekaterina O. Gubernatorova
Int. J. Mol. Sci. 2022, 23(7), 3521; https://doi.org/10.3390/ijms23073521 - 24 Mar 2022
Cited by 8 | Viewed by 3677
Abstract
Combined anti-cytokine therapy is a promising therapeutic approach for uncontrolled steroid-resistant asthma. In this regard, simultaneous blockade of IL-4 and IL-13 signaling by Dupilumab (anti-IL-4Ra monoclonal antibody) was recently approved for severe eosinophilic asthma. However, no therapeutic options for neutrophilic asthma are currently [...] Read more.
Combined anti-cytokine therapy is a promising therapeutic approach for uncontrolled steroid-resistant asthma. In this regard, simultaneous blockade of IL-4 and IL-13 signaling by Dupilumab (anti-IL-4Ra monoclonal antibody) was recently approved for severe eosinophilic asthma. However, no therapeutic options for neutrophilic asthma are currently available. Recent advances in our understanding of asthma pathogenesis suggest that both IL-6 and TNF may represent potential targets for treatment of severe neutrophilic asthma. Nevertheless, the efficacy of simultaneous pharmacological inhibition of TNF and IL-6 in asthma was not yet studied. To evaluate the potency of combined cytokine inhibition, we simultaneously administrated IL-6 and TNF inhibitors to BALB/c mice with HDM-induced asthma. Combined IL-6/TNF inhibition, but not individual blockade of these two cytokines, led to complex anti-inflammatory effects including reduced Th2-induced eosinophilia and less prominent Th17/Th1-mediated neutrophilic infiltrate in the airways. Taken together, our results provide evidence for therapeutic potential of combined IL-6/TNF inhibition in severe steroid-resistant asthma. Full article
(This article belongs to the Special Issue Immune Cells in Allergy and Inflammation)
Show Figures

Figure 1

Back to TopTop